The Trump administration has decided not to impose tariffs on generic drugs, narrowing the scope of its ongoing pharmaceutical trade investigation.The Wall Street Journal carry the report. More:Officials confirmed that the White House is no longer actively considering Section 232 tariffs on generic pharmaceuticals under the national-security probe initiated earlier this year. The decision follows internal debate over whether to use tariffs to bring drug manufacturing back to the U.S.President Trump had previously threatened 100% tariffs on name-brand drugs, though he later delayed implementation to allow for negotiations with pharmaceutical companies. Generics—accounting for roughly 90% of all U.S. prescriptions—will be exempt for now, according to White House and Commerce Department spokespeople.The move marks a major scaling-back of the Commerce Department’s initial investigation, which had targeted both generic and non-generic medicines as well as drug ingredients. It also reverses an earlier campaign pledge to restore production of essential generic drugs to the United States. This article was written by Eamonn Sheridan at investinglive.com.